

Iain B Mcinnes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9312059/publications.pdf>

Version: 2024-02-01

100
papers

20,181
citations

28274

55
h-index

33894

99
g-index

101
all docs

101
docs citations

101
times ranked

19279
citing authors

#	ARTICLE	IF	CITATIONS
1	Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2010, 69, 631-637.	0.9	1,711
2	Rheumatoid arthritis. Nature Reviews Disease Primers, 2018, 4, 18001.	30.5	1,441
3	The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. Annual Review of Medicine, 2015, 66, 311-328.	12.2	1,074
4	Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet, The, 2017, 389, 2328-2337.	13.7	942
5	EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Annals of the Rheumatic Diseases, 2017, 76, 17-28.	0.9	918
6	Immunopathogenesis of Rheumatoid Arthritis. Immunity, 2017, 46, 183-196.	14.3	780
7	European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Annals of the Rheumatic Diseases, 2016, 75, 499-510.	0.9	743
8	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2015, 386, 1137-1146.	13.7	722
9	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet, The, 2013, 382, 780-789.	13.7	688
10	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Annals of the Rheumatic Diseases, 2014, 73, 62-68.	0.9	659
11	MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11193-11198.	7.1	644
12	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. New England Journal of Medicine, 2015, 373, 1329-1339.	27.0	629
13	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 700.1-712.	0.9	609
14	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Annals of the Rheumatic Diseases, 2014, 73, 990-999.	0.9	576
15	Tendinopathy. Nature Reviews Disease Primers, 2021, 7, 1.	30.5	388
16	How Cytokine Networks Fuel Inflammation: Toward a cytokine-based disease taxonomy. Nature Medicine, 2013, 19, 822-824.	30.7	341
17	Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nature Medicine, 2020, 26, 1295-1306.	30.7	304
18	Inflammatory mechanisms in tendinopathy – towards translation. Nature Reviews Rheumatology, 2017, 13, 110-122.	8.0	269

#	ARTICLE	IF	CITATIONS
19	State-of-the-art: rheumatoid arthritis: Figure 1. Annals of the Rheumatic Diseases, 2010, 69, 1898-1906.	0.9	268
20	Role for TNF in atherosclerosis? Lessons from autoimmune disease. Nature Reviews Cardiology, 2009, 6, 410-417.	13.7	252
21	Inflammation is Present in Early Human Tendinopathy. American Journal of Sports Medicine, 2010, 38, 2085-2091.	4.2	241
22	Molecular Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response Phenotypes. Cell Reports, 2019, 28, 2455-2470.e5.	6.4	241
23	Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry, the, 2019, 6, 164-173.	7.4	238
24	Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Annals of the Rheumatic Diseases, 2015, 74, 694-702.	0.9	237
25	Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Annals of the Rheumatic Diseases, 2013, 72, 211-216.	0.9	224
26	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. Annals of the Rheumatic Diseases, 2019, 78, 761-772.	0.9	219
27	Clinical applications of machine learning algorithms: beyond the black box. BMJ: British Medical Journal, 2019, 364, l886.	2.3	213
28	Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet, The, 2020, 395, 1126-1136.	13.7	206
29	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2020, 79, 760-770.	0.9	205
30	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet, The, 2020, 395, 1496-1505.	13.7	178
31	Synovial tissue research: a state-of-the-art review. Nature Reviews Rheumatology, 2017, 13, 463-475.	8.0	175
32	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 2021, 80, 71-87.	0.9	158
33	Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs. New England Journal of Medicine, 2021, 385, 628-639.	27.0	156
34	Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. PLoS Medicine, 2019, 16, e1002739.	8.4	144
35	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. New England Journal of Medicine, 2021, 384, 1227-1239.	27.0	143
36	MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease. Nature Communications, 2015, 6, 6774.	12.8	141

#	ARTICLE	IF	CITATIONS
37	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020, 395, 427-440.	13.7	122
38	Tendon and ligament mechanical loading in the pathogenesis of inflammatory arthritis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 193-207.	8.0	122
39	Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1806-1812.	0.9	119
40	Hypoxia: a critical regulator of early human tendinopathy. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 302-310.	0.9	118
41	A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1020-1030.	0.9	117
42	Managing rheumatic and musculoskeletal diseases – past, present and future. <i>Nature Reviews Rheumatology</i> , 2017, 13, 443-448.	8.0	117
43	Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). <i>Arthritis Research and Therapy</i> , 2018, 20, 47.	3.5	117
44	Immune-mediated inflammatory disease therapeutics: past, present and future. <i>Nature Reviews Immunology</i> , 2021, 21, 680-686.	22.7	106
45	Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. <i>Nature Reviews Rheumatology</i> , 2021, 17, 585-595.	8.0	99
46	MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12970.	12.8	97
47	Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. <i>Nature Reviews Rheumatology</i> , 2019, 15, 461-474.	8.0	95
48	IL-17A mediates inflammatory and tissue remodelling events in early human tendinopathy. <i>Scientific Reports</i> , 2016, 6, 27149.	3.3	89
49	Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1739-1749.	3.4	87
50	Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1642-1652.	0.9	85
51	Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. <i>Journal of Rheumatology</i> , 2016, 43, 1713-1717.	2.0	77
52	Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol. <i>Trials</i> , 2019, 20, 429.	1.6	77
53	Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1015-1018.	0.9	77
54	JAK inhibitors and infections risk: focus on herpes zoster. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093605.	2.7	72

#	ARTICLE	IF	CITATIONS
55	Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1949-1952.	0.9	63
56	S100A8 & S100A9: Alarmin mediated inflammation in tendinopathy. <i>Scientific Reports</i> , 2019, 9, 1463.	3.3	61
57	Tranexamic acid toxicity in human periarticular tissues. <i>Bone and Joint Research</i> , 2019, 8, 11-18.	3.6	56
58	Tumour necrosis factor α blockade reduces circulating N-terminal pro-brain natriuretic peptide levels in patients with active rheumatoid arthritis: results from a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1281-1285.	0.9	53
59	Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. <i>British Journal of Dermatology</i> , 2020, 182, 130-137.	1.5	52
60	MicroRNA29a Treatment Improves Early Tendon Injury. <i>Molecular Therapy</i> , 2017, 25, 2415-2426.	8.2	51
61	Psoriatic arthritis from a mechanistic perspective. <i>Nature Reviews Rheumatology</i> , 2022, 18, 311-325.	8.0	49
62	Alarmins in tendinopathy: unravelling new mechanisms in a common disease. <i>Rheumatology</i> , 2013, 52, 769-779.	1.9	48
63	Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 604-616.	5.6	48
64	Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 359-369.	0.9	47
65	Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. <i>Rheumatology</i> , 2021, 60, 2109-2121.	1.9	44
66	Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. <i>RMD Open</i> , 2021, 7, e001838.	3.8	42
67	Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 475-485.	5.6	41
68	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	3.8	36
69	COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. <i>JCI Insight</i> , 2021, 6, .	5.0	35
70	Targeting danger molecules in tendinopathy: the HMGB1/TLR4 axis. <i>RMD Open</i> , 2017, 3, e000456.	3.8	33
71	Single cell and spatial transcriptomics in human tendon disease indicate dysregulated immune homeostasis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1494-1497.	0.9	33
72	Small-molecule therapeutics in rheumatoid arthritis: Scientific rationale, efficacy and safety. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014, 28, 605-624.	3.3	32

#	ARTICLE	IF	CITATIONS
73	Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features. RMD Open, 2020, 6, e001376.	3.8	31
74	Brief Report: Predicting Functional Disability: Oneâ€Year Results From the Scottish Early Rheumatoid Arthritis Inception Cohort. Arthritis and Rheumatology, 2016, 68, 1596-1602.	5.6	29
75	Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study. Annals of the Rheumatic Diseases, 2010, 69, 1251-1252.	0.9	28
76	Brief Report: Proatherogenic Cytokine Microenvironment in the Aortic Adventitia of Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2016, 68, 1361-1366.	5.6	27
77	New strategies to control inflammatory synovitis: interleukin 15 and beyond. Annals of the Rheumatic Diseases, 2003, 62, 51ii-54.	0.9	25
78	Mast Cells Contribute to<i>Porphyromonas gingivalisâ€induced Bone Loss. Journal of Dental Research, 2016, 95, 704-710.	5.2	25
79	Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2Âyears: results from the FUTURE 2 study. Arthritis Research and Therapy, 2018, 20, 113.	3.5	24
80	Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. Lancet Rheumatology, The, 2021, 3, e337-e346.	3.9	24
81	The Scottish Early Rheumatoid Arthritis (SERA) Study: an inception cohort and biobank. BMC Musculoskeletal Disorders, 2016, 17, 461.	1.9	22
82	Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation<i>in Vitro</i>. Journal of Rheumatology, 2017, 44, 748-756.	2.0	22
83	Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. Modern Rheumatology, 2022, 32, 1-11.	1.8	21
84	Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis. Atherosclerosis, 2016, 254, 167-171.	0.8	20
85	Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, 1815-1823.	2.0	20
86	Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials. RMD Open, 2021, 7, e001679.	3.8	19
87	Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies. Rheumatology, 2021, 60, 5337-5350.	1.9	18
88	Translational targeting of inflammation and fibrosis in frozen shoulder: Molecular dissection of the T cell/IL-17A axis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	18
89	Efficacy of ustekinumab in biologic-naÃve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. RMD Open, 2019, 5, e000990.	3.8	17
90	Responsiveness of Serum Câ€Reactive Protein, Interleukinâ€17A, and Interleukinâ€17F Levels to Ustekinumab in Psoriatic Arthritis: Lessons From Two Phase III, Multicenter, Doubleâ€Blind, Placeboâ€Controlled Trials. Arthritis and Rheumatology, 2019, 71, 1660-1669.	5.6	13

#	ARTICLE	IF	CITATIONS
91	Reflections on “older” drugs: learning new lessons in rheumatology. Nature Reviews Rheumatology, 2020, 16, 179-183.	8.0	13
92	Europe rules on harm from fluoroquinolone antibiotics. Nature, 2019, 566, 326-326.	27.8	12
93	Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naïve Patients from 2 Phase III Ustekinumab Trials. Journal of Rheumatology, 2019, 46, 1458-1461.	2.0	11
94	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open, 2021, 7, e001845.	3.8	11
95	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD Open, 2022, 8, e002195.	3.8	11
96	The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions. Journal of Allergy and Clinical Immunology, 2021, 148, 941-952.	2.9	9
97	Immunoglobulin A antibodies to oxidized collagen type II as a potential biomarker for the stratification of spondyloarthritis from rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2020, 49, 281-291.	1.1	5
98	Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. Arthritis and Rheumatology, 2022, 74, 1184-1192.	5.6	5
99	BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study. BMC Rheumatology, 2021, 5, 22.	1.6	4
100	OP0114 MACHINE LEARNING TOOLS IDENTIFY PATIENT CLUSTERS AND SWOLLEN AND TENDER JOINT CORRELATION PATTERNS IN A LARGE DATABASE FROM THE SECUKINUMAB PSORIATIC ARTHRITIS CLINICAL DEVELOPMENT PROGRAM. , 2019, , .		1